{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06432647",
            "orgStudyIdInfo": {
                "id": "ATH-1105-0101"
            },
            "organization": {
                "fullName": "Athira Pharma",
                "class": "INDUSTRY"
            },
            "briefTitle": "A SAD and MAD Study of the Safety, Tolerability, and Pharmacokinetics of ATH-1105",
            "officialTitle": "ATH-1105 A Phase 1, Double-Blind, Placebo-Controlled, Single-and-Multiple-Oral-Dose, Safety, Tolerability, and Pharmacokinetic Study in Healthy Male and Female Subjects",
            "therapeuticArea": [
                "Other"
            ],
            "study": "a-sad-and-mad-study-of-the-safety-tolerability-and-pharmacokinetics-of-ath"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-04-24",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-10-15",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-10-15",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-05-17",
            "studyFirstSubmitQcDate": "2024-05-22",
            "studyFirstPostDateStruct": {
                "date": "2024-05-29",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-22",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-29",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Athira Pharma",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "Fortrea Holdings, Inc.",
                    "class": "UNKNOWN"
                }
            ]
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The goal of this Phase 1 interventional study is to assess the safety, tolerability and pharmacokinetics of ATH-1105 in healthy male and female participants.",
            "detailedDescription": "The study is a Phase 1, First-In-Human study consisting of two parts (A and B). Part A will comprise a single-dose, double-blind, placebo-controlled, sequential-group design. Part B will comprise a multiple-dose, placebo-controlled, sequential-group design."
        },
        "conditionsModule": {
            "conditions": [
                "Healthy Volunteers"
            ],
            "keywords": [
                "ATH-1105"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "OTHER",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 80,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "ATH-1105",
                    "type": "EXPERIMENTAL",
                    "description": "Part A: ATH-1105 administered once as an oral solution.\n\nPart B: ATH-1105 administered once daily as an oral solution for 10 days.",
                    "interventionNames": [
                        "Drug: ATH-1105"
                    ]
                },
                {
                    "label": "Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Part A: Placebo administered once as an oral solution\n\nPart B: Placebo administered once daily as an oral solution",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "ATH-1105",
                    "description": "ATH-1105 in oral form. Participants will be administered ATH-1105 once in Part A and once daily for 10 days in Part B.",
                    "armGroupLabels": [
                        "ATH-1105"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Placebo in oral form. Participants will be administered Placebo once in Part A and once daily for 10 days in Part B.",
                    "armGroupLabels": [
                        "Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence of Treatment-Emergent Adverse Events",
                    "description": "Safety and tolerability of single or multiple ascending doses of ATH-1105 as measured by incidence of AEs, determined by clinical laboratory tests, physical examinations, vital signs measurements, and 12-lead ECG",
                    "timeFrame": "Part A: Up to 7 days post-dose, Part B: Up to 7 days post final dose on day 10"
                },
                {
                    "measure": "Severity of Treatment-Emergent Adverse Events",
                    "description": "Treatment-emergent adverse events will be graded on a 1 through 5 scale, based on severity as determined by the principal investigator.",
                    "timeFrame": "Part A: Up to 7 days post-dose, Part B: Up to 7 days post final dose on day 10"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Area under the plasma concentration time curve (AUC)",
                    "description": "AUC will be determined from all collected plasma samples from baseline through up to 48 hours post-dose.",
                    "timeFrame": "Part A: Up to 48 hours post-dose, Part B: Up to 48 hours post final dose on Day 10"
                },
                {
                    "measure": "Maximum observed plasma concentration (Cmax)",
                    "description": "Cmax will be determined from all collected plasma samples from baseline through up to 48 hours post-dose.",
                    "timeFrame": "Part A: Up to 48 hours post-dose, Part B: Up to 48 hours post final dose on Day 10"
                },
                {
                    "measure": "Time to maximum observed plasma concentration (Tmax)",
                    "description": "Tmax will be determined from all collected plasma samples from baseline through up to 48 hours post-dose.",
                    "timeFrame": "Part A: Up to 48 hours post-dose, Part B: Up to 48 hours post final dose on Day 10"
                },
                {
                    "measure": "Half-life (t1/2)",
                    "description": "t1/2 will be determined from all collected plasma samples from baseline through up to 48 hours post-dose.",
                    "timeFrame": "Part A: Up to 48 hours post-dose, Part B: Up to 48 hours post final dose on Day 10"
                },
                {
                    "measure": "Amount of IMP excreted unchanged in the urine (Ae)",
                    "description": "Amount of IMP excreted unchanged in the urine will be determined from all collected urine samples from baseline through up to 48 hours post-dose",
                    "timeFrame": "Part A: Up to 48 hours post-dose, Part B: Up to 48 hours post final dose on Day 10"
                },
                {
                    "measure": "IMP Concentration in Cerebrospinal Fluid",
                    "description": "Amount of IMP in the urine will be determined from all collected CSF samples from baseline through up to 48 hours post-dose",
                    "timeFrame": "Will occur at calculated maximum plasma concentration."
                },
                {
                    "measure": "Accumulation Ratio (AUC) of IMP in Urine",
                    "description": "Accumulation Ratio in urine will be determined from all collected urine samples from baseline through up to 48 hours post-dose",
                    "timeFrame": "Part A: Up to 48 hours post-dose, Part B: Up to 48 hours post final dose on Day 10"
                },
                {
                    "measure": "Accumulation Ratio (AUC) of IMP in Plasma",
                    "description": "Accumulation Ratio in plasma will be determined from all collected plasma samples from baseline through up to 48 hours post-dose",
                    "timeFrame": "Part A: Up to 48 hours post-dose, Part B: Up to 48 hours post final dose on Day 10"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Body mass index between 18.0 and 32.0 kg/m2 inclusive.\n* In good health, determined by no clinically significant findings from medical history, 12-lead ECG, vital signs measurements, and clinical laboratory evaluations at screening and check-in or predose on Day 1\n* Females will not be pregnant or lactating, and females of childbearing potential and males will agree to use contraception\n* Able to comprehend and willing to sign an ICF and to abide by the study restrictions.\n\nExclusion Criteria:\n\nMedical Conditions:\n\n* Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder\n* History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance\n* History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs\n* Any of the following:\n\n  1. QTcF \\>450 ms in males or \\>470 ms in females\n  2. QRS duration \\>110 ms\n  3. PR interval \\>220 ms\n  4. Findings which would make QTc measurements difficult or QTc data uninterpretable.\n  5. History of additional risk factors for torsades de pointes\n* Confirmed systolic blood pressure \\>140 or \\<90 mmHg, diastolic blood pressure \\>90 or \\<50 mmHg, and pulse rate \\>100 or \\<40 beats per minute.\n* Positive hepatitis panel and/or positive human immunodeficiency virus test\n* Part B only: Current psychiatric disorder, suicidal ideation in the previous 2 years (as assessed by the Columbia-Suicide Severity Rating Scale \\[C-SSRS\\]), or a lifetime suicide attempt.\n\nPrior/concomitant therapy:\n\n* Administration of any vaccine in the 30 days prior to dosing.\n* Use or intend to use any medications/products known to alter drug absorption, metabolism, or elimination processes\n* Use or intend to use any prescription medications/products other than hormone replacement therapy, oral, implantable, transdermal, injectable, or intrauterine contraceptives within 14 days prior to dosing\n* Use or intend to use slow-release medications/products considered to still be active within 14 days prior to check-in\n* Use or intend to use any nonprescription medications/products including vitamins, minerals, and phytotherapeutic/herbal/plant-derived preparations within 7 days prior to check-in",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "65 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Javier San Martin, MD",
                    "role": "CONTACT",
                    "phone": "425-620-8501",
                    "email": "info@athira.com"
                }
            ],
            "locations": [
                {
                    "facility": "Fortrea Clinical Research Unit Inc.",
                    "status": "RECRUITING",
                    "city": "Dallas",
                    "state": "Texas",
                    "zip": "75247",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Jhande Gardiner",
                            "role": "CONTACT",
                            "phone": "214-647-9399",
                            "email": "jhande.gardiner@fortrea.com"
                        },
                        {
                            "name": "Adeyemi Gbohunmi, MD, PhD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.78306,
                        "lon": -96.80667
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M21860",
                    "name": "Pharmaceutical Solutions",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "PhSol",
                    "name": "Pharmaceutical Solutions"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}